CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
Blinded study medicationdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03098563
NCT03098563Phase 2Completed
CompareCT.gov

Maximizing Analgesia to Reduce Pain Sensitivity in Chronic Knee Osteoarthritis Pain Patients

Johns Hopkins University·interventional·Posted Apr 4, 2017·Updated Dec 11, 2024

In Brief

A Phase 2 clinical trial evaluating Blinded study medication for Knee Osteoarthritis. Completed, enrolled 58 participants across 1 site.

Detailed Summary

This research is being done to evaluate whether combining medications that are FDA approved, but have not yet been approved for combination treatment, can be effective in reducing pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Osteoarthritis
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 4, 2017
Enrollment StartNov 1, 2017
Primary CompletionNov 17, 2023
Study CompletionNov 27, 2023
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 9.2 years ago

Interventions

Blinded study medicationdrug

Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.